India's RFCL Braves Into The Stronghold Of MNCs With High-end Diagnostics; Will It Become The Next Takeover Candidate?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Having identified a distinct cost advantage over its bigger Western counterparts, RFCL - India's largest in-vitro diagnostics and laboratory solutions firm - is branching out into the manufacture of high-end diagnostic products used for immunoassays, a range of molecular diagnostic kits and theranostics, bringing it a step closer toward personalized medicine